Published in J Clin Invest on August 01, 1959
Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther (2006) 1.80
Serum biochemical values in rheumatoid disease. Ann Rheum Dis (1971) 1.77
Tubular secretion of urate in man. J Clin Invest (1959) 1.60
Coexistent rheumatoid arthritis and tophaceous gout: a case report. Ann Rheum Dis (1981) 1.48
A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther (2006) 1.43
Epidemiology of gout. Rheum Dis Clin North Am (2014) 1.28
Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol (2011) 1.23
THE RENAL EXCRETION OF OXYPURINES. J Clin Invest (1965) 1.21
MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS. J Clin Invest (1963) 1.09
Effect of atromid and its components on uric acid excretion and on gout. Ann Rheum Dis (1965) 1.08
Evidence for a postsecretory reabsorptive site for uric acid in man. J Clin Invest (1973) 1.02
Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One (2012) 1.01
Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol (2008) 0.94
Genetic studies in primary gout. Investigations on the plasma levels of the urate-binding alpha 1-alpha 2-globulin in individuals from two gouty kindreds. J Clin Invest (1968) 0.93
Diflunisal: a review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans. Br J Clin Pharmacol (1977) 0.93
Urate-2-14C transport in the rat nephron. J Clin Invest (1971) 0.92
Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest (1985) 0.86
Pyrazinoate excretion in the chimpanzee. Relation to urate disposition and the actions of uricosuric drugs. J Clin Invest (1973) 0.86
Uricosuric agents in the treatment of gout. Ann Rheum Dis (1960) 0.83
The relation between secretion of urate and p-aminohippurate in the rabbit kidney. J Physiol (1967) 0.83
The effect of tiaprofenic acid on uric acid excretion in man. Drugs (1988) 0.81
Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis (2013) 0.81
Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. Front Pharmacol (2016) 0.78
Coexisting ankylosing spondylitis and gouty arthritis. Clin Rheumatol (2007) 0.76
Current concepts of hyperuricemia and gout. Calif Med (1969) 0.75
Diagnosis of gout. Br Med J (1972) 0.75
The uricosuric action of azapropazone: dose-response and comparison with probenecid. Br J Clin Pharmacol (1984) 0.75
Gout: the last 50 years. J R Soc Med (1996) 0.75
The effects of oral salicylate on serum uric acid levels. Can Med Assoc J (1963) 0.75
Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers. Eur J Clin Pharmacol (2010) 0.75
THE RENAL CLEARANCES OF SUBSTITUTED HIPPURIC ACID DERIVATIVES AND OTHER AROMATIC ACIDS IN DOG AND MAN. J Clin Invest (1945) 27.11
Non-ionic diffusion and the excretion of weak acids and bases. Am J Med (1958) 4.09
The excretion of salicylate. Br J Pharmacol Chemother (1955) 2.32
Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout. Am J Med (1957) 2.24
A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther (1957) 2.20
The renal mechanism for urate excretion in man. J Clin Invest (1950) 2.19
Salicylate and salicyl conjugates: fluorimetric estimation, biosynthesis and renal excretion in man. J Clin Invest (1958) 1.92
Evaluation of uricosuric agents in chronic gout. Ann Rheum Dis (1957) 1.91
Effect of sodium lactate infusion on urate clearance in man. Proc Soc Exp Biol Med (1957) 1.81
Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. J Clin Invest (1952) 1.77
Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects. J Clin Invest (1953) 1.71
Value of uricosuric agents and in particular of G. 28 315 in gout. Ann Rheum Dis (1958) 1.66
Paradoxical retention of uric acid by uricosuric drugs in low dosage. Proc Soc Exp Biol Med (1955) 1.65
The kidney. Annu Rev Physiol (1954) 1.51
A study, by simultaneous clearance techniques, of salicylate excretion in man: effect of alkalinization of the urine by bicarbonate administration; effect of probenecid. J Clin Invest (1955) 1.50
Therapeutic value of probenecid (benemid) in gout. J Am Med Assoc (1952) 1.46
The diagnosis of gout; significance of an elevated serum uric acid value. N Engl J Med (1958) 1.41
Some recent advances in the study of uric acid metabolism and gout. Bull N Y Acad Med (1951) 1.20
The influence of urinary pH on the renal excretion of salicyl derivatives during aspirin therapy. J Lab Clin Med (1950) 1.19
Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum (1958) 1.18
Thiosulphate clearance in pregnancy. J Clin Invest (1950) 1.17
Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents. Bull N Y Acad Med (1958) 1.12
Effect of pyrazinamide and pyrazinoic acid on urate clearance and other discrete renal functions. Proc Soc Exp Biol Med (1957) 1.10
Gout, a derangement of purine metabolism. Adv Intern Med (1952) 1.10
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians (1951) 1.09
Zoxazolamine: physiological disposition, uricosuric properties. Am J Med (1958) 1.04
Electromigration on filter paper of uric acid from serum and synovial fluid. Science (1958) 1.03
Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent. J Clin Invest (1956) 0.93
Sodium salicylate and probenecid in the treatment of chronic gout; assessment of their relative effects in lowering serum uric acid levels. Ann Rheum Dis (1954) 0.93
The effect of salicylic acid and acetylsalicylic acid on uric acid excretion and plasma uric acid concentration in the normal human subject. Acta Pharmacol Toxicol (Copenh) (1955) 0.93
Inhibition of the uricosuric action of benemid by salicylate. J Lab Clin Med (1955) 0.82
Probenecid and salicylates: the question of interaction in terms of penicillin excretion. J Lab Clin Med (1955) 0.81
Incorporation of glycine nitrogen into uric acid in normal and gouty man. Metabolism (1952) 2.38
Serum alkaline phosphatase activity in diseases of the skeletal and hepatobiliary systems. A consideration of the current status. Am J Med (1959) 2.25
Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout. Am J Med (1957) 2.24
A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther (1957) 2.20
The renal mechanism for urate excretion in man. J Clin Invest (1950) 2.19
Current principles of management in gout. Am J Med (1952) 1.99
EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. Am J Med (1964) 1.93
Effect of sodium lactate infusion on urate clearance in man. Proc Soc Exp Biol Med (1957) 1.81
Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects. J Clin Invest (1952) 1.77
Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects. J Clin Invest (1953) 1.71
A further study of the utilization of dietary glycine nitrogen for uric acid synthesis in gout. J Clin Invest (1953) 1.65
Paradoxical retention of uric acid by uricosuric drugs in low dosage. Proc Soc Exp Biol Med (1955) 1.65
Present status of atherosclerosis as a derangement of lipid metabolism. Am J Med (1953) 1.61
Effects of diet in essential hypertension. II. Results with unmodified Kempner rice diet in 50 hospitalized patients. Am J Med (1950) 1.61
Tubular secretion of urate in man. J Clin Invest (1959) 1.60
Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med (1961) 1.59
A study, by simultaneous clearance techniques, of salicylate excretion in man: effect of alkalinization of the urine by bicarbonate administration; effect of probenecid. J Clin Invest (1955) 1.50
The purine bases of human urine. I. Separation and identification. J Biol Chem (1957) 1.40
Renal function in Wilson's disease. J Clin Invest (1957) 1.34
The physiological disposition of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material. J Pharmacol Exp Ther (1963) 1.33
A simultaneous study of glycine-N15 incorporation into uric acid and heme, and of Fe59 utilization, in a case of gout associated with polycythemia secondary to congenital heart disease. Am J Med (1953) 1.32
Effects of diet in essential hypertension. I. Baseline study: effects in 86 cases of prolonged hospitalization on regular hospital diet. Am J Med (1950) 1.30
On the biosynthesis of uric acid from glycine-N15 in primary and secondary polycythemia. Am J Med (1956) 1.23
A three-component system for regulation of renal excretion of uric acid in man. Trans Assoc Am Physicians (1961) 1.22
Incorporation of glycine-1-C14, glycine-2-C14 and glycine-N15 into uric acid in normal and gouty subjects. Am J Med (1958) 1.21
Some recent advances in the study of uric acid metabolism and gout. Bull N Y Acad Med (1951) 1.20
Primary and secondary gout. Ann Intern Med (1953) 1.19
Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum (1958) 1.18
Origin of urinary creatine in progressive muscular dystrophy. Metabolism (1952) 1.14
SIGNIFICANCE OF THE RENAL CLEARANCE OF URIC ACID IN NORMAL AND GOUTY MAN. Am J Med (1964) 1.13
AN ABNORMALITY OF GLUTAMINE METABOLISM IN PRIMARY GOUT. Am J Med (1963) 1.12
Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents. Bull N Y Acad Med (1958) 1.12
Effect of pyrazinamide and pyrazinoic acid on urate clearance and other discrete renal functions. Proc Soc Exp Biol Med (1957) 1.10
Gout, a derangement of purine metabolism. Adv Intern Med (1952) 1.10
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians (1951) 1.09
MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS. J Clin Invest (1963) 1.09
A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dog. Am J Med (1960) 1.08
Biochemical pharmacological considerations of phenylbutazone and its analogues. Ann N Y Acad Sci (1960) 1.08
Prevention and treatment of chronic gouty arthritis. J Am Med Assoc (1955) 1.07
Phenylbutazone metabolites: antirheumatic, sodium-retaining and uricosuric effects in man. J Pharmacol Exp Ther (1958) 1.07
Zoxazolamine: physiological disposition, uricosuric properties. Am J Med (1958) 1.04
Effects of adrenocorticotropic hormone (ACTH) in gout. Am J Med (1950) 1.03
Drug reactions characterized by cholestasis associated with intrahepatic biliary tract obstruction. Am J Med (1957) 1.02
Occurrence of methylated purine bases in yeast ribonucleic acid. J Biol Chem (1958) 1.01
The purine bases of human urine. II. Semiquantitative estimation and isotope incorporation. J Biol Chem (1957) 1.00
Ultrafiltrability of plasma urate in man. Proc Soc Exp Biol Med (1953) 0.99
Tubular secretion of urate in the dog. Am J Physiol (1960) 0.98
Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione). Proc Soc Exp Biol Med (1955) 0.97
Hyperuricemia induced by the administration of chlorthalidone and other sulfonamide diuretics. Am J Med (1962) 0.96
Relationship between pKa and uricosuric activity in phenylbutazone analogues. Nature (1958) 0.95
Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent. J Clin Invest (1956) 0.93
Intramolecular distribution of uric acid-N15 after administration of glycine-N15 and ammonium-N15 chloride to goury and non-goury subjects. J Clin Invest (1962) 0.92
Mobilization of gouty tophi by protracted use of uricosuric agents. Am J Med (1951) 0.91
Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout. Trans Assoc Am Physicians (1954) 0.90
Renal function in gout. II. Effect of uric acid loading on renal excretion of uric acid. Am J Med (1962) 0.90
The search for uricosuric agents suited to the management of tophaceous gout. N Y State J Med (1963) 0.90
Suppression of tubular secretion of urate by pyrazinamide in the dog. Proc Soc Exp Biol Med (1962) 0.89
The concept of secondary gout; relation to purine metabolism in polycythemia and myeloid metaplasia. Trans Assoc Am Physicians (1956) 0.88
Effect of drugs that alter uric acid excretion in man on uric acid clearance in the chicken. Am J Physiol (1960) 0.87
Chromatographic investigation of purines in normal human urine. Proc Soc Exp Biol Med (1954) 0.86
The identification of 6-succinoaminopurine and of 8-hydroxy-7-methylguanine as normal human urinary constituents. J Biol Chem (1957) 0.86
A view of gout as inborn error of metabolism. Am J Med (1960) 0.85